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This systematic review examines the efficacy of oral ginger for dysmenorrhea. Key biomedical databases and grey literature were
searched. We included randomized controlled trials comparing oral ginger against placebo or active treatment in women with
dysmenorrhea. Six trials were identified. Two authors independently reviewed the articles, extracted data, and assessed risk of
bias. Discrepancies were resolved by consensus with a third reviewer. We completed a narrative synthesis of all six studies and
exploratory meta-analyses of three studies comparing ginger with placebo and two studies comparing ginger with a nonsteroidal
anti-inflammatory drug (NSAID). Ginger appeared more effective for reducing pain severity than placebo. The weighted mean
difference on a 10 cm visual analogue scale was 1.55 cm (favoring ginger) (95% CI 0.68 to 2.43). No significant difference was
found between ginger and mefenamic acid (an NSAID). The standardized mean difference was 0 (95% CI −0.40 to 0.41). Available
data suggest that oral ginger could be an effective treatment for menstrual pain in dysmenorrhea. Findings, however, need to be
interpreted with caution because of the small number of studies, poormethodological quality of the studies, and high heterogeneity
across trials. The review highlights the need for future trials with high methodological quality.
1. Introduction
Dysmenorrhea is characterized by low abdominal or pelvic
pain occurring before or during menstruation [1]. It can be
either primary (in the absence of an identifiable pathological
condition) or secondary (due to organic pathology such as
endometriosis or fibroids) [1]. In addition to pelvic pain,
some women with dysmenorrhea may also experience low
back pain, nausea, vomiting, and changes in bowel habits
[1, 2]. Dysmenorrhea is highly prevalent among women of
reproductive age, with an estimated prevalence between 16%
and 91% [3]. As the leading cause of absenteeism from work
or school amongwomen [4], dysmenorrhea negatively affects
individual women and society as a whole. The impact of
dysmenorrhea can even extend beyond the time of menstru-
ation in that dysmenorrhea leads to increased pain sensitivity
among affected women [5, 6]. Such increased pain sensitivity
and other shared mechanisms of pain (e.g., inflammation)
may explain why dysmenorrhea commonly cooccurs with
other chronic pain conditions (e.g., irritable bowel syndrome,
low back pain, and chronic headache) [6]. Scholars suggest
that such increased pain sensitivity may predispose women
to developing pain later in life [6]. Better management of
dysmenorrhea may not only improve women’s quality of life,
but also reduce their risk of developing future pain [5, 6].
Dysmenorrhea is conventionally treated with nons-
teroidal anti-inflammatory drugs (NSAIDs) or oral contra-
ceptive pills (OCPs) [2], the efficacy of which are supported
by research evidence [7, 8]. However, NSAIDs and OCPs
have limitations: some women with dysmenorrhea do not
respond to NSAIDs or OCPs (with an estimated failure rate
of >15% for NSAIDs) [2, 4]; some cannot use these medica-
tions because of contraindications or adverse effects; some
prefer not to use any medications. Therefore, investigation
of complementary alternative treatments for dysmenorrhea
is warranted. With a long history of medicinal use that dates
back over 2,500 years, ginger rhizome has played an impor-
tant role in Chinese and Indian medicine [9]. Oral ginger has
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been used to treat pain from dysmenorrhea, osteoarthritis,
rheumatoid arthritis, andmigraine, as well as gastrointestinal
symptoms such as nausea, vomiting, diarrhea, and indiges-
tion [9]. Ginger is one of the most commonly used natural
products among women with dysmenorrhea [10]. The exact
mechanism of action of ginger in pain relief remains to
be elucidated; however, some evidence suggests that the
constituents of ginger have anti-inflammatory and analgesic
properties [11]. Furthermore, preclinical research shows that
ginger suppresses the synthesis of prostaglandin (through
inhibition of cyclooxygenase) and leukotrienes [9], which are
involved in dysmenorrhea pathogenesis [2].
Two systematic reviews examined the efficacy of ginger
for general pain relief (acute and chronic pain) [12, 13] and
included the few early trials specific to ginger in dysmen-
orrhea [14, 15]. During finalization of our paper, a review
of ginger for primary dysmenorrhea was published [16], but
findings were limited by several factors including potential
author bias from conflict of financial interest, a less stringent
evaluation of study bias, problematic selection of trial data
for effect size calculations, and exclusion of comparisons of
ginger with NSAIDs (widely used in dysmenorrhea manage-
ment) in meta-analysis. Thus, a more rigorous and thorough
systematic review and meta-analysis is merited. The purpose
of this review was to systematically summarize and critically
evaluate the evidence from clinical trials of oral ginger for the
treatment of dysmenorrhea.The research question was as fol-
lows: In women with dysmenorrhea (population/problem),
is oral ginger (intervention) as compared to placebo control
or other interventions (comparison) efficacious in reducing
menstrual pain (primary outcome)?
2. Methods
A prospective protocol was developed following the Coch-
rane Handbook (http://handbook.cochrane.org/) [17]. It in-
cluded a description of the research question, search strategy,
inclusion criteria, data extraction, and evaluation criteria.The
protocol was registered on the international prospective regi-
ster of systematic reviews PROSPERO (CRD42015016-
744) and can be accessed at http://www.crd.york.ac.uk/
PROSPERO/display record.asp?ID=CRD42015016744. We
followed the PreferredReporting Items for Systematic Review
and Meta-Analysis (PRISMA) statement [18] for the report-
ing structure of this review.
2.1. Search Strategies. We searched the following electronic
databases: PubMed, EMBASE,Cochrane Library, Cumulative
Index to Nursing and Allied Health Literature (CINAHL),
Web of Science Core Collection (including Science Citation
Index, Social Science Citation Index, and Conference Pro-
ceedings Citation Index), PsycINFO, the Allied and Comple-
mentaryMedicineDatabase (AMED), LILACS, International
Pharmaceutical Abstracts, and Biological Abstracts.Websites
of clinical trial registries (including ClinicalTrial.gov, World
Health Organization International Clinical Trial Registry
Platform) were searched to identify unpublished trial data.
We also searched grey literature (i.e., research that is not
formally published in journal articles) through Open Grey
and Grey Literature Report. Unpublished trial data and grey
literature were searched to minimize potential publication
bias [17].
The search strategy was (ginger∗ OR zingiber∗ OR zinz-
iber OR gingifere OR gingembre OR Jiang OR shokyo) AND
(dysmenor∗ OR menstr∗ OR “period∗ pain” OR “painful
period∗”). Words were searched as free text. Following the
Cochrane Handbook [17], no restrictions in language or
publication date were applied. Bilingual colleagues were
sought to assist with translating non-English publications.
All the databases and websites were searched from their
respective inceptions to May 2015. Reference lists of the
retrieved articles and previous reviews were hand-searched
to identify relevant studies.
2.2. Study Selection. We included those trials in which oral
ginger was used as a primary, sole, and not a combined
therapy and compared against a placebo or active treatment
inwomenwith dysmenorrhea.We included only randomized
controlled trials reporting menstrual pain severity assessed
by a patient-reported outcomemeasure (e.g., visual analogue
scale or verbal rating scale). The exclusion criteria were
(1) trials of ginger combined with other potentially active
substances, (2) trials of nonoral use of ginger (e.g., ginger
moxibustion, essential oil massage), (3) nonhuman or in vitro
studies, and (4) observational studies.
All three authors were involved in reviewing and extract-
ing data. Two reviewers extracted data from the included
trials independently: first author (CC) reviewed all studies;
the second and third authors (BB andKK) each reviewed half.
Disagreements were resolved by discussion and consensus
with assistance from the third reviewer. A standard data-
coding table was developed for extracting data from individ-
ual trials.The following data were extracted: participant char-
acteristics, sample size, form and dosage of ginger, control
intervention, assessment of adherence, outcome measures,
methods for statistical analysis, study findings, and adverse
events reported. For the outcome data, we extracted the
sample sizes of the ginger and control groups, themean values
and standard deviations for continuous outcomes, and fre-
quencies for ordinal outcomes. Where missing information
was detected or clarification was needed, we attempted to
contact the authors of the primary studies via email.
The Cochrane Collaboration’s tool was used for assessing
risk of bias in individual studies [17]. This tool allows
for assessing risk of bias for individual domains includ-
ing random sequence generation, allocation concealment,
blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective reporting,
and other sources of bias (e.g., bias from contamination, bias
from carry-over effect, and bias from conflict of interest).
Risk of bias for each domain was judged as “high,” “low,”
or “unclear” (when too few details were available to make
a judgment of “high” or “low” risk). Two of the reviewers
independently assessed risk of bias. Disagreements were
resolved by discussion and consensus with assistance from
the third reviewer.
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Data extracted from the included trials were synthesized
narratively. Tabulation was used to juxtapose trial character-
istics (i.e., participants, intervention, comparison, and out-
come measures) and findings. Patterns across the trials were
identified in terms of trial characteristics and study findings.
Factors that might have influenced the results were further
explored. We rated the overall quality of evidence (high,
moderate, low, or very low) using the GRADE approach [19].
Based on this approach, randomized controlled trials without
serious limitations are rated as high quality. However, the
overall quality of evidence can be downgraded depending on
the presence of each of the following factors: high likelihood
of bias, indirectness of evidence, imprecision of results,
unexplained heterogeneity or inconsistency of results, and
publication bias. The quality rating falls by one level for each
factor [19].
Where available, we used outcome data from the intent-
to-treat analysis to calculate effect sizes. For continuous
outcomes, we calculated mean difference (where the same
scale was used across studies) or standardized mean differ-
ence (where different scales were used across studies) corre-
sponding to Cohen’s 𝑑. For ordinal outcomes, we calculated
Cliff ’s delta [20] and subsequently converted the value to
Cohen’s 𝑑. We conducted exploratory meta-analysis using
random-effects models [17]. 𝐼2 was used as the measure of
heterogeneity. A funnel plot to assess publication bias was
not possible because of the limited number of studies (<10)
included in the review [17]. RevMan 5.3 and R software were
used for the meta-analyses.
3. Results
3.1. Description of Studies. Figure 1 provides a flow diagram
of studies identified, screened, included, and excluded for
the systematic review and meta-analysis. Six trials met
criteria and were included in the systematic review. All
the trials were identified through database searching; no
relevant unpublished trials or grey literature were identified.
We found one paper published in Persian [21] that, with
translation assistance, was determined to very likely be a
preliminary report of one of the included studies (published
in English) [15]. Therefore, the Persian study was excluded
to avoid possible duplication of data. Table 1 summarizes key
characteristics of each study.
All included studies were of parallel design. Among
the six studies, five were conducted in Iran [14, 15, 22–24]
and one in India [25]. Participants were either college or
high school students. Five of the six studies included only
women with moderate to severe symptoms [14, 15, 22–24].
Four studies specified the inclusion of women with pri-
mary dysmenorrhea only, excluding women with secondary
dysmenorrhea [14, 15, 23, 24]; however, it is unclear how
secondary dysmenorrhea was defined/diagnosed. Across the
studies, the sample sizes of the ginger group ranged from
𝑁 = 25 to𝑁 = 61.
All included trials tested ginger in the form of crude dry
powder. It was mentioned in three studies that ginger was
processed in an Iranian manufacturing plant [14, 15, 23], but
the exact origin of the ginger is not clear across the studies.
The quantity of active constituents of ginger was neither
tested nor reported in any of the studies. The daily dose
of powdered ginger ranged from 750mg to 2,000mg. The
most common duration and timing of ginger treatment was
three days (the first three days of menstruation) [14, 22, 25].
Rahnama et al. tested a five-day regimen (starting two
days before menstruation) followed by a three-day regimen
(starting the first day of the subsequent menstruation) within
the same group of participants [15]. Kashefi et al. used a
four-day regimen starting the day before menstruation [24],
and Shirvani et al. [23] tested an individualized regimen in
which participantswere asked to take ginger capsules daily till
their menstrual pain was relieved. Participants were typically
given ginger and followed for only one cycle, Kashefi et al.
being the only exception with ginger being given for two
cycles [24]. Adherence to treatment was evaluated only in
one study, in which participants were asked to report the
number of capsules they took [14]. Ginger was comparedwith
placebo in three trials, two two-arm trials involving ginger
and placebo [15, 22] and one three-arm trial involving ginger,
placebo, and zinc [24]. Two trials compared ginger with
NSAIDs [14, 23].More specifically, ginger was comparedwith
mefenamic acid in a two-arm trial [23] and with mefenamic
acid and ibuprofen in a three-arm trial [14].Halder conducted
a three-arm trial comparing ginger with progressive muscle
relaxation (PMR) and an unspecified control condition.
To measure pain severity, four studies [15, 22–24] used
the visual analogue scale (VAS), a continuous numerical scale
comprised of a 10 cm line. Two studiesmeasured pain severity
using ordinal scales: Ozgoli et al. measured pain severity
using 4-point verbalmultidimensional scoring system (VMS)
[14]; Halder measured symptoms severity on a 5-point Likert
scale with little information about the scale being reported
[25]. Only Halder reported severity of pain at more than one
location (e.g., low abdomen and low back) as well as nonpain
symptoms (e.g., nausea, vomiting, and diarrhea) using a 5-
point Likert scale. Pain duration was assessed in two studies.
In Shirvani et al. [23], “days in pain” data were collected;
in Rahnama et al. [15], “hours in pain” data were collected.
Timing of outcome assessment varied. In two trials [24,
25], participants were asked to rate their symptom severity
every 24 hours. In Shirvani et al. [23], symptom severity
was rated retrospectively on the last day of menstruation. In
the remaining three studies [14, 15, 22], specific timing for
outcome assessment was unclear.
3.2. Risk of Bias in the Included Studies. Figure 2 summarizes
the risk of bias for each study. For random sequence genera-
tion, three included studies were judged as having a low risk
of bias. In each of these three trials [15, 22, 24], it was reported
that a table of random numbers was used. Ozgoli et al. [14]
were judged as being at high risk ofbias because an alternate
assignment approach was used. In the remaining two studies
[23, 25], random assignment was stated but the authors gave
no detail on the sequence generation.
Allocation concealment was judged as low risk in two
studies: In Rahnama et al. [15], allocation lists were man-
aged centrally by a midwife. Kashefi et al. [24] stated that
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Figure 1: PRISMA flow diagram.
the capsules were identical in appearance and coded by the
pharmacologist. Ozgoli et al. [14] was rated at high risk of
bias because participants were alternatively allocated into the
groups. In the remaining three studies [22, 23, 25], there was
insufficient information to assess allocation concealment.
Only one trial was double-blinded (participants and
personnel) [15], where packets were coded and capsules were
described as identical in appearance, color, smell, and taste.
Two trials had a high risk of bias: In one trial [14], ginger
and NSAIDs were produced by different pharmacological
companies, which made it possible to identify pills. In the
other trial [25], blinding was not possible because of the
different types of interventions used (i.e., ginger versus PMR).
Information was insufficient to assess blinding participants
and personnel in the remaining three studies [22–24].
Attrition was acceptable in four studies: There was no
attrition in Shirvani et al. [23], Jenabi [22], and Ozgoli
et al. [14], and the attrition was low and balanced across
groups (5.3% and 6.5%) in Kashefi et al. [24]. In Rahnama
et al. [15], however, there was differential attrition, with 22%
dropping out of the placebo group and 0% dropping out of
the ginger group. In addition, intent-to-treat analysis was not
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used in this study, which caused high risk of bias related to
incomplete outcome data. Information about attrition was
unclear in Halder [25].
For bias related to selective reporting, none of the trials
was prospectively registered in the trial registries that we
searched, which precluded us from comparing a protocol
with a published report. As an alternative, we compared the
outcomes listed in the purpose statement or methods section
with the reported results. We judged reporting bias as low for
all studies except for Halder [25] in which the severities of
some symptomswere identified in the purpose statement, but
not reported in the results.
“Other risk of bias” was judged as high in two studies.
In Shirvani et al. [23], there was differential use of extra
analgesics between the ginger group and the NSAID group
with higher usage in the ginger group. In Rahnama et al. [15],
the effects observed for Protocol 2 (three-day treatment) were
biased by always being preceded by effects of Protocol 1 (five-
day treatment) (i.e., potential carry-over effect). In addition,
there was a high risk of contamination between groups since
the participants were from the same dormitory. For the rest
of the studies [14, 22, 24, 25], “other risk of bias” was unclear
due to lack of information. None of the trials declared sources
of funding or conflicts of interest.
3.3. Effects of Interventions. All included studies reported
beneficial effects of ginger. For three of the studies comparing
ginger with placebo [15, 22, 24], ginger was reported to be
more effective than placebo in reducing pain severity (see
Figure 3 for effect sizes). In addition, one study reported that
pain duration (assessed by hours in pain) was significantly
reduced with a five-day ginger regimen compared to placebo
[15]. For two studies comparing ginger with NSAIDs, the
researchers found no significant difference in pain severity
between ginger and NSAIDs: Ozgoli et al. [14] reported
no significant difference between ginger, mefenamic acid,
and ibuprofen; Shirvani et al. [23] reported no significant
difference between ginger and mefenamic acid (see Figure 3
for effect sizes). In the single study that evaluated pain
duration, no significance difference between ginger and
mefenamic acid was reported [23]. Halder [25] compared
ginger with PMR and control, finding that both ginger and
PMR reduced symptoms of dysmenorrhea, but ginger was
more effective in terms of reducing cramping and colicky
pain, lower abdominal pain, nausea, and diarrhea.
Two trials [15, 24] reported side effects of ginger. Heart-
burn was reported in both studies, with occurrence rates
of 2.1% and 5.1% [15, 24], and headache was reported in
one study, with occurrence rates of 2.1 and 2.2% across two
menstrual cycles [24]. No significant difference was found
between the groups with respect to side effects [24].
We conducted exploratorymeta-analyses on three studies
that compared ginger with placebo and on two studies that
compared ginger with mefenamic acid (an NSAID). Data
were excluded from the meta-analyses in cases where no
other study compared ginger with a specific comparison
group (PMR [25], zinc [24], ibuprofen [14]), where the control
condition was inadequately described [25], or where the data
were potentially biased by a previous treatment cycle or
protocol (i.e., potential carry-over effect) [15, 24].
Results of meta-analysis suggest that ginger was more
effective for reducing pain severity than placebo (Figure 4).
The weighted mean difference on the VAS scale was 1.55 cm
(favoring ginger) (95% CI 0.68 to 2.43). Results of meta-
analysis for ginger versus mefenamic acid failed to show
any difference in pain severity between the two treatments
(Figure 4). The standardized mean difference was 0 (95% CI
−0.40 to 0.41). Statistical heterogeneity between studies was
very high based on the inconsistency index (𝐼2 = 79% for
ginger versus placebo, 𝐼2 = 74% for ginger versus NSAIDs).
We were unable to conduct meta-analyses on any of the
secondary outcomes that we specified in our protocol (i.e.,
other dimensions of pain and other dysmenorrhea symp-
toms) because of insufficient data.
4. Discussion
This review summarizes evidence from six clinical trials
evaluating the efficacy of oral ginger for dysmenorrhea. The
available data suggest a promising pattern of oral ginger as
a potentially effective treatment for pain in dysmenorrhea.
Overall, ginger was reported as more effective for pain
relief than placebo, and no significant difference was found
between ginger and NSAIDs. These findings, however, need
to be interpreted with great caution due to the small number
of studies, poor methodological quality, and high hetero-
geneity across the trials. Based on the GRADE framework
to assess cumulative evidence [19], we judged the overall
quality of evidence as “low.” We downgraded the quality
of evidence from high to low because of the likelihood of
bias and unexplained heterogeneity. In addition to the issue
of internal validity, external validity of the evidence is a
concern. All the included trials were conducted in Asia.
Pharmacogenetics and outcome expectancy regarding ginger
intervention could differ across cultures and ethnicities, and
therefore, it is uncertain whether the results can be general-
ized to women worldwide. Research conducted in Western
countries (US and Denmark) supports the analgesic effect of
ginger for arthritis pain [26] and muscle pain after exercise
[27]. Presumably, ginger may have analgesic effect among
Western women. However, in the context of dysmenorrhea,
this premise should be further tested.
In terms of safety, the included trials suggest that ginger
is relatively safe, with reported side effects (heartburn and
headache) being infrequent and the numbers of adverse
events similar for ginger and placebo groups [15, 24]. This is
consistent with previous report that ginger has a good safety
profile when used appropriately [9, 12, 13]. One systematic
review suggests that, as pain treatment, ginger has a superior
safety profile to NSAIDs, indicated by fewer gastrointestinal
side effects and renal risks [13]. Given the safety profile and
preliminary evidence of efficacy, ginger may be appropriate
for women with dysmenorrhea who cannot or prefer not to
use conventional medications. Patient values and preferences
would play a crucial role in treatment decision making.
Ginger, however, needs to be used with caution for people
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Figure 2: Risk of bias summary: review authors’ judgments about
each risk of bias domain for each included study.
who takeNifedipine and anticoagulants due to potential drug
interactions [9].
The findings of the current review are consistent with
two previous reviews of ginger for pain, which concluded
that there is preliminary support of the efficacy of ginger
on pain conditions such as osteoarthritis and dysmenorrhea
[12, 13]. Findings are also similar, but less positive than
those of a recent review by Daily et al. [16]. Daily et al.
report a more favorable conclusion regarding the efficacy
ginger for dysmenorrhea than we describe here. According
to Daily et al. [16], the included trials had “low or moderate”
risk of bias and that ginger is “highly effective for treating
dysmenorrhea” (p. 2252). In contrast, we gave more “high
risk of bias” ratings for included trials. For example, we
followed Cochrane Handbook recommendations [17] and
judged “alternate assignment” as high risk of bias for allo-
cation concealment, whereas Daily et al. did not. The effect
size for ginger versus placebo fromDaily et al. [16] was larger
than that in our review (∼2.2 versus 1.55 on a 10 point scale).
This is because, for trials with two-cycle treatment, Daily et
al. extracted data from Cycle 2, but we extracted data from
Cycle 1. We did that to prevent potential carry-over effect and
to make included trials more comparable to each other. Our
review also differs from Daily et al. in other significant ways.
We prospectively registered the review protocol to increase
transparency and safeguard against selective reporting [17].
In addition, our meta-analysis compares ginger not only
with placebo, but also with NSAIDs. Given the wide use of
NSAIDs among women with dysmenorrhea, the information
about comparative efficacy may be useful for researchers
and clinicians. Finally, authorship of the Daily et al. article
included the president of a dietary supplement company
that manufactures ginger supplements, which present the
potential for bias.
The current review has several limitations. First, though
we believe our search strategy was systematic and compre-
hensive (not limited to papers published in English), we may
have missed relevant trials that were only accessible through
non-English databases. Second, the meta-analyses were by
nature exploratory, serving to provide a crude overview of
the overall direction and magnitude of the results. Because
of the high heterogeneity among the studies, results of our
meta-analysis must be interpreted with caution. Third, given
the limited number of studies and limited quality of the
included trials, it was not possible for us to explore sources
of heterogeneity through subgroup analysis (e.g., subgroup
analysis of high quality studies) or metaregression (e.g., to
evaluate dose-response relationships).
There is a strong need to improve the methodological
quality of future trials. Future trials need to use appro-
priate methods for random sequence generation, allocation
concealment, blinding participants and personnel, blinding
outcome assessors, addressing incomplete data (including
using intent-to-treat analysis), and reporting prespecified
outcomes. Effective blinding is particularly important in
designing future trials. Ginger has a distinct aroma and
taste, which poses a major methodological challenge in
blinding. If blinding is ineffective, the observed effects may
be inflated due to positive expectations. Because none of
the trials assessed the success of blinding, it is not possible
to ascertain if blinding was effective. Research has shown
that participants receiving bottles with ginger capsules could
correctly identify the bottle 75% of the time; however, when
participants received ginger capsuleswithout containers, they
could no longer differentiate between ginger and placebo
[28]. A subsequent study demonstrated that ginger could be
effectively blinded by using blister packs which minimize the
aroma [29]. We recommend that future researchers follow
this approach and, at the same time, systematically assess
the effectiveness of blinding. In addition, future trials should
carefully address potential confounding variables (e.g., use
of other analgesics and hormonal contraceptives) through
study design or analysis. Future trials need to be appropriately
powered. Although power analysis was stated in four trials
[14, 15, 22, 23], none of them specified the effect size that was
used for calculation. In addition, for the two trials comparing
ginger and NSAIDs [14, 23], it was problematic to conclude
that ginger was as effective as NSAIDs, because neither trial
was designed as an equivalence or noninferiority trial. Future
researchers comparing ginger with NSAIDs are encouraged
to design noninferiority trials and to power the study with a
specified noninferiority margin.
Future publications need to fully describe the methods of
trials especially regarding key aspects of the design and ginger
preparations. None of the available trials quantified and/or
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reported the amount of ingredients in ginger preparations.
Without such information, it is challenging tomake between-
study comparisons and clinical recommendations. We urge
researchers to consult the CONSORT statement specific to
herbal medicine trials [30] when designing and reporting
trials. Meanwhile, to allow assessment of publication bias
and outcome reporting bias, prospectively registering trials
is recommended.
This review suggests potential benefits of oral ginger in
managing dysmenorrhea pain; however, the findings need
to be interpreted with caution due to the shortcomings
in available trials and the exploratory nature of our meta-
analysis. Future trials need to be rigorous in design and
delivery, with adequate reporting of trial details to enable
appraisal and interpretation of results.
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